Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income (loss)	$ 5,501	$ (3,380)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Amortization of premium or discount on fixed maturity securities	179	529
Net realized (gain) loss on sale of investments	(186)	(27)
Unrealized (gain) loss on trading securities	76	(66)
Unrealized (gain) loss on derivative liability - embedded conversion feature	(7,260)
Equity-based compensation expense	384	129
Changes in assets and liabilities:
Accrued investment income	105	10
Other assets	(193)	391
Change in cash equivalents held in trust	2,284	(4,798)
Change in restricted cash	(597,141)	9
Losses and loss adjustment reserves	(10,660)	(9,477)
Losses payable	(285)	(1,091)
Unearned premiums	(160)	(127)
Accrued ceding commission expense	(5)	(52)
Accrued interest on notes payable	(15)	21
Other liabilities	715	(698)
Total adjustments	(612,162)	(15,247)
Net cash (used in) provided by operating activities:	(606,661)	(18,627)
Cash flows from investing activities:
Purchase of investments	(100,472)	(249,770)
Proceeds from sales and maturities of investments	41,045	251,655
Net cash (used in) provided by investing activities:	(59,427)	1,885
Cash flows from financing activities:
Proceeds from issuance of preferred stock and warrants to purchase common stock	600,000	22,572
Fees incurred and paid relating to preferred stock and warrant issuance	(4,276)	(3,234)
Series B preferred stock dividends paid in cash	(3,498)
Deferred offering costs		(12,048)
Notes payable – principal repayments	(2,300)
Notes payable – principal issued	918	1,929
Net cash provided by (used in) financing activities:	590,844	9,219
(Decrease) increase in cash and cash equivalents	(75,244)	(7,523)
Cash and cash equivalents, beginning of period	78,009	78,009
Cash and cash equivalents, end of period	2,765
Cash paid during the period:
Interest	51	1,500
Supplementary disclosure of non-cash investing and financing activities:
Embedded derivatives on preferred stock issuances	66,227
Notes payable issued in lieu of cash interest payments	918	1,929
Non-cash preferred series B dividends accreted	750
Accrued fees relating to series B preferred stock issuance	27,284
Preferred deemed dividend recorded due to beneficial conversion feature		$ 9,455